Introduction
============

Familial adenomatous polyposis (FAP) is an autosomal dominant inherited disorder with an incidence of approximately 3--10/100,000 ([@b1-mmr-18-02-1423]). FAP is characterized by the presence of hundreds to thousands of adenomatous polyps in the colon and rectum, and is a disease predisposing individuals to colorectal cancer (CRC) ([@b2-mmr-18-02-1423]). Affected FAP subjects without early diagnosis and treatment subsequently develop CRC in the late childhood to the sixties, with a mean age at diagnosis of 40 years old ([@b3-mmr-18-02-1423]). CRC is the third most common malignant disease in both males and females in Asia, and is the second leading cause of cancer death in the past ten years ([@b4-mmr-18-02-1423]). Patients who suffer from FAP also have increased risk of extra-colonic manifestations, including duodenal polyposis, sebaceous cysts, congenital hypertrophy of the retinal pigment epithelium (CHRPE) and tumors in the upper gastrointestinal tract, thyroid gland and brain ([@b5-mmr-18-02-1423],[@b6-mmr-18-02-1423]).

Germline mutations in the tumor suppressor adenomatous polyposis coli gene (APC) on chromosome 5q22.2 are responsible for the most cases of FAP. The APC gene comprises of 16 exons (NM_000038.5), including1 upstream non-coding exon and 15 coding exons. The last coding exon encompasses the majority (\>75%) of the total coding region. Most of the mutations causing FAP are nonsense or frameshift mutations, and can result in premature stop codons thus produce truncated APC proteins ([@b7-mmr-18-02-1423]). The APC protein, which comprises of 2843 amino acids, plays an important role in the β-catenin nuclear localization ([@b8-mmr-18-02-1423]). Loss of APC function results in increased level of β-catenin and activation of growth-promoting genes via the increased β-catenin/Tcf-4 transcription complexes, subsequently leading to the development of adenomatous colorectal polyps at a young age ([@b9-mmr-18-02-1423]). Adenomatous polyposis will consequently progress to CRC if left untreated.

Genetic screening along with other preventative strategies can conspicuously improve the overall survival of FAP patients. In the present study, we screened for novel mutations that might cause FAP in a four-generation Chinese family with FAP using targeted next-generation sequencing method. A novel mutation in the exon 10 of APC (c.1317delA) was identified in all of the affected members, but not in the unaffected members or the 600 normal controls. In addition, this mutation was correlated to extra-colonic phenotypes featuring by duodenal polyposis and sebaceous cysts in this pedigree. This novel mutation can hopefully be utilized as a biomarker for molecular diagnosis and precise treatment in the foreseeable future.

Materials and methods
=====================

### Subjects

The family with FAP was recruited from Hospital of University of Electronic Science and Technology of China and Sichuan Provincial People\'s Hospital ([Fig. 1](#f1-mmr-18-02-1423){ref-type="fig"}). This study was conducted in accordance to the tenets of the Declaration of Helsinki and approved by the Institutional Review Boards of Sichuan Academy of Medical Sciences and Sichuan Provincial People\'s Hospital. Written informed consents were obtained from the family prior to the study. 600 unrelated normal control subjects were recruited from participants who attended to the annual physical examination in Sichuan Provincial People\'s Hospital. They underwent comprehensive examinations and were free from any related diseases.

### Clinical diagnosis

Twelve of the family members were diagnosed with FAP. Non-consanguineous marriages were found in the four-generation family and their clinical information is summarized in [Table I](#tI-mmr-18-02-1423){ref-type="table"}. All the available members in this family were enrolled in our study and underwent complete clinical examination. Patient III: 7, diagnosed and treated in Sichuan Provincial People\'s Hospital, was the proband of this family ([Fig. 1](#f1-mmr-18-02-1423){ref-type="fig"}). FAP was confirmed in the family by endoscopic screening. The diagnostic criteria were as follows: ([@b1-mmr-18-02-1423]) more than 100 colorectal polyps in total, and ([@b2-mmr-18-02-1423]) at least 20 synchronous adenomatous polyps ([Fig. 2](#f2-mmr-18-02-1423){ref-type="fig"}). All patients\' clinical information, family history, and the results of colonoscopic, laboratory, and pathologic examinations were collected. We obtained 5--10 ml of peripheral blood from as many families members as possible, with full informed consent, and reviewed pathologic slides whenever available.

### DNA extraction

All genomic DNA was extracted from peripheral blood using a blood DNA extraction kit (QIAamp DNA Blood Midi kit; Qiagen GmbH, Hilden, Germany) according to the manufacturer\'s protocol. DNA samples were stored at −20°C until used. DNA integrity was evaluated by 1% agarose gel electrophoresis and NanoDrop 2000 (Thermo Fisher Scientific, Inc., Waltham, MA, USA).

### Targeted next-generation sequencing and variant detection

In accordance with the literatures searched within online databases, a total of 200 candidate genes associated with colorectal cancer and ID/DD were selected as the genes of interest. We used a custom-designed gene panel, synthesized using the Agilent Sure-Select Target Enrichment technique (Zhongguancun Huakang Gene Institute, China), to capture the coding regions from the 200 genes, including their exons and exon-intron boundaries (1.285M bp in total). The following targeted next-generation sequencing (NGS) was performed on an Illumina GAIIx platform (Illumina, Inc., San Diego, CA, USA) using paired-end sequencing of 110 bp for two patients (III:7 and III:9). Bioinformatics analysis of the raw data included the following steps: i) image analysis using RTA software version 1.9 (real-time analysis, Illumina); ii) base calling using CASAVA software v1.8.2 (Illumina); iii) filtered out duplicate and low base quality score reads using the Genome Analysis Tool kit (GATK; Broad Institute) version 4; iv) aligned clean paired-end reads to the human reference genome build hg19 using BWA software (Pittsburgh Supercomputing Center, Pittsburgh, PA, U.S.A.) and v) identified insertion-deletions (indels) and single-nucleotide polymorphisms (SNPs) using the GATK and annotated using ANNOVAR (version 2017, July 16). The sequencing depth was more than 5X (range of 5X-185X; average of 136X), and the mean coverage was 98.56%. The detected variants were annotated and filtered based on public and in-house databases: i) Variants within intergenic, intronic, and UTR regions and synonymous mutations were excluded from downstream analysis and ii) variants in dbSNP138 (<http://www.ncbi.nlm.nih.gov/projects/SNP/>), 1000 Genomes Project (<ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp>), YH Database (<http://yh.genomics.org.cn/>), and HapMap Project (<ftp://ftp.ncbi.nlm.nih.gov/hapmap>) were excluded. Heterozygous variations of genes with autosomal dominant heredity were regarded as likely causative variations. We performed validation and parental origin analyses for these variations by conventional Sanger sequencing, and confirmed causative mutations according to parental origin of the variations and clinical features of the patients.

### Mutation validation

The heterozygous APC (NM_000038.5) mutation identified by targeted NGS was further confirmed in all the family members and 600 normal controls by direct sequencing. Primers flanking the mutation were designed based on genomic sequences of Human Genome database and synthesized by Invitrogen; Thermo Fisher Scientific, Inc.: APC-F: GGGTTATATTAGTGATCCCTGCA; APC-R: ACACAGAGGAAGCAGCTGAT. Amplified PCR products were purified with spin columns (QIAquick; Qiagen, Inc., Valencia, CA, USA) and sequenced directly (BigDye Terminators Sequencing kit; Applied Biosystems; Thermo Fisher Scientific, Inc.) in both directions with an automated genetic analysis system (3730; ABI; Thermo Fisher Scientific, Inc.). Multiple sequence alignment of the human APC protein was performed along with other APC protein across different species, to check for the conservation of the residues. The homology modelling server SWISS-MODEL ([www.swissmodel.expasy.org/](www.swissmodel.expasy.org/)) was used to predict the tertiary structure of APC protein.

### Brief Literature review

A systematic literature search was conducted using the PubMed, Embase, Web of Science, and the Chinese Biomedical Database, in order to identify all published studies on the APC mutations of Han Chinese FAP subjects from their starting date to December 31, 2017. Two observers (YL and MP) independently piled up data from all eligible publications onto paper data collection forms. Disagreements were resolved by discussion until a consensus was achieved. Otherwise, two other investigators (BG and ZY) were consulted to resolve the dispute. The search strategy was based on the following search term/phase, 'Familial adenomatous polyposis or FAP', 'adenomatous polyposis coli gene or APC' and 'Chinese'. The eligible articles were considered if they: i) evaluated germline mutations of APC gene in Chinese FAP families and ii) were original research articles, not reviews or comments. The articles selected were limited to studies in humans and in Han Chinese, but without restriction on sample size or time period. Excluded were abstracts from conferences, full texts without raw data available for retrieval, republished data, duplicate studies, association studies and reviews. A total of 79 Han Chinese families from 20 independent studies (including the current study) were included (some of the studies reported more than one family). All the mutations in the APC gene were coordinated using the same transcript reference NM_000038.5.

Results
=======

### Clinical findings

A four-generation family composed of 29 members from Sichuan Province of China was recruited in this study. Among them, I1, I2, II1, II2, and II3 were deceased before this study, their information were collected from their medical records. III3 was deceased after he participated in this study and donated his blood sample. In total, 12 family members were diagnosed with FAP according to their clinical features, family history, medical history, colonoscopy, and pathology examinations. The disease exhibited a pattern of autosomal dominant inheritance, as indicated by the familial pedigree ([Fig. 1](#f1-mmr-18-02-1423){ref-type="fig"}). Detailed clinical information was presented in [Table I](#tI-mmr-18-02-1423){ref-type="table"}.

Extracolonic manifestations featuring by duodenal polyposis and sebaceous cysts were observed in all the available patients of this family, indicating a correlation with this novel mutation. The proband (III:7) had obvious duodenal polyposis, and was diagnosed with CRC at the age of 42 year old; while his cousin (III:15) had an onset of CRC at 43 year old. Two grape beaded polyps and multiple small polyps were present in the transverse colon and descending colon of the proband ([Fig. 2](#f2-mmr-18-02-1423){ref-type="fig"}). The mean age of diagnosis of polyposis was 30.5 years old among the patients in this family. The daughter (IV:5) and son (IV:6) of the proband had an aggressive phenotype with early onset of the polyposis at younger age of 16 and 21 years old, respectively.

### Targeted next-generation sequencing and mutation validation

To ensure complete sequencing coverage of all coding regions in APC, the quality and reliability of NGS data were evaluated based on the percentage of readable bases and the coverage depth in the targeted region. In the APC gene, the coverage depth was up to 200×, with 100% of bases being readable in coding regions. This suggests high capacity for variant identification in most of the exons. Additionally, the mean depth was close to the median depth in each exon, indicating a good randomicity. On average, 295 variations within the 200 genes were found in the two patients (III:7 and III:9). Under the autosomal dominant model, 8 novel variations were filtered out. Because previously unclassified variations and pathogenic mutations detected by NGS were considered as causative candidate, the filtered data was narrowed down to a pathogenic heterozygous variant (c.1317delA in the APC gene). This variant was further validated using Sanger sequencing on other family members and 600 normal controls. Finally, we confirmed the novel heterozygous deletion mutation c.1317delA (p.Ala440LeufsTer14; [Fig. 3A](#f3-mmr-18-02-1423){ref-type="fig"}) in exon 10 of APC in the all of the affected members, and this mutation was absent in the unaffected member and the other 600 normal controls. Genotypes and phenotypes for the patients with APC mutations were described in [Table I](#tI-mmr-18-02-1423){ref-type="table"}. Therefore, this mutation was co-segregated with the phenotype in this family. Comparative amino acid sequence alignment of other APC protein across different species revealed that this novel mutation occurred at highly conserved positions ([Fig. 3B](#f3-mmr-18-02-1423){ref-type="fig"}). This mutation is a 1-bp deletion of A at exon 10 (c.1317delA), leading to a subsequent reading frame-shift and producing a premature termination codon located at the 454th amino acid downstream (p.Ala440LeufsTer14). This premature termination consequently resulted in a truncation of 2,389 amino acids downstream of APC protein ([Fig. 4](#f4-mmr-18-02-1423){ref-type="fig"}). To further study the pathogenicity of this mutation, protein tertiary structures of wild type and p.Ala440LeufsTer14 mutation of APC were predicted using the SWISS-MODEL. According to the tetramer, the mutated APC protein lost C-terminal helices (2,389 amino acids downstream), which was an important region to bind with β-catenin, microtubule and other elements ([Fig. 4](#f4-mmr-18-02-1423){ref-type="fig"}).

### Brief literature review of the APC mutations in Han Chinese

All the mutations that were hitherto reported were listed in [Table II](#tII-mmr-18-02-1423){ref-type="table"}. We have retrieved 20 individual studies (including the current study). In total, there were 79 Han Chinese FAP families included, and 54 different APC mutations reported. Among the mutations, 59.3% (32/54) were frameshift mutations, 24.1% (13/54) were nonsense mutations, 3.7% (2/54) were missense mutations, 7.4% (4/54) were large deletions and 5.5% (3/54) were intronic variants.

There were three main hotspot mutation sites in the APC gene: i) c.3180-c.3187/codon 1061--1062, which was in the β-catenin binding domain of APC, accounted for 12.7% (10/79) of the occurrence; ii) c.3921-c.3931/codon 1307--1309, which was in the mutation cluster region (MCR), accounted for 25.3% (20/79) of the occurrence; and iii) c.5432C\>T (p.Ser1811Leu), which was in the β-catenin binding and down-regulation domain, accounted for 3.8% (3/79) of the occurrence. In total, these hotspot mutations accounted for 41.8% of the overall occurrence.

Discussion
==========

Familial adenomatous polyposis (FAP) refers to an autosomal dominant inherited condition, which is characterized by the early onset of numerous adenomatous colorectal polyps. Approximately 50% of FAP patients develop adenomas at the age of 15, and it increases to 95% by the age of 35 years old ([@b10-mmr-18-02-1423]). In many FAP patients, extra colonic manifestations are observed, including gastric and duodenal polyps, congenital hypertrophy of the retinal pigment epithelium (CHRPE), sebaceous cysts, and tumors in the upper gastrointestinal tract, thyroid gland and brain ([@b5-mmr-18-02-1423],[@b6-mmr-18-02-1423]). In this pedigree, a novel frameshift mutation c.1317delA (p.Ala440LeufsTer14) in the APC gene was identified. The proband has the heterozygous mutation, so theoretically he inherited the mutant strand from his father (who was also a patient) and the wild-type strand from his mother (who was healthy). But unfortunately we are not able to validate the phenotypes of the proband\'s father and mother, because both of them passed away. However, we noticed that the novel mutation was correlated to extra colonic manifestations featuring by duodenal polyposis and sebaceous cysts. In addition, FAP patients also have a high lifetime risk of colorectal cancer (CRC), which is one of the most common forms of cancer in the world ([@b10-mmr-18-02-1423],[@b11-mmr-18-02-1423]). In this family, patient III:7 (proband) and III:15 have been already diagnosed with CRC at the age of 42 and 43 respectively. Considering FAP-related CRC takes many years to develop, and the overall mean age of onset for CRC is 40 years old ([@b3-mmr-18-02-1423]), unfortunately it\'s possible that other patients in this family may still have a high risk of CRC as time goes by. As a result, early diagnosis and routine medical monitoring are remarkably crucial for the FAP patients.

Genetic diagnosis mainly focuses on the APC gene in chromosome 5q22.2, as mutations in this gene almost account for all cases of FAP ([@b12-mmr-18-02-1423]). The APC gene encodes a tumor suppressor protein, which is responsible for ubiquitination and degradation of β-catenin and functions as an antagonist of the Wnt signaling pathway ([@b13-mmr-18-02-1423],[@b14-mmr-18-02-1423]). β-catenin is an important factor in cell cycle entry, proliferation, differentiation, migration, apoptosis, and progression. Abnormal accumulation of β-catenin and aberrant activation of Wnt/β-catenin pathway leads to progression of several major human cancers ([@b15-mmr-18-02-1423],[@b16-mmr-18-02-1423]). In addition, APC also involves in other processes including cell migration and adhesion, transcriptional activation, microtubule stabilization and apoptosis. Inactivation of APC can lead to defective chromosome segregation and aberrant mitosis ([@b17-mmr-18-02-1423]--[@b19-mmr-18-02-1423]). In the present study, we detected a novel frame shift mutation c.1317delA (p.Ala440LeufsTer14) in the exon 10 of the APC gene in a large Chinese FAP pedigree. This mutation could result in a truncation of 2,389 amino acids downstream of APC protein. Protein tertiary structure analysis revealed that the mutated APC protein lost C-terminal helices, which was an important region to bind with β-catenin, microtubule and other elements.

Hitherto, more than 4,600 APC mutations have been reported according to Leiden Open Variation Database (LOVD; databases.lovd.nl/shared/genes/APC). However, these mutations are related to numerous diseases, mainly gastric cancer. And they are not confined to a certain population. Given that FAP-related CRC only accounts for approximately 1% of overall CRC ([@b2-mmr-18-02-1423]) and ethnical difference might exist among different populations, we conducted a brief literature review and focused on the APC mutation spectrum only in the Han Chinese FAP population. According to our findings, among the 4,600 reported mutations, only 54 were related to Han Chinese FAP. Truncating mutations, including frameshift mutations (59.3%), nonsense mutations (24.1%) and large deletions (7.4%), account for an overall percentage of 90.8%. While non-truncating mutations, including missense mutations (3.7%) and intronic mutations (5.5%), account for the rest 9.2%. These findings support that direct sequencing of APC gene could still be the gold standard and the most accurate method in genetic diagnosis of FAP. In fact, there are several other alternative methods for gene testing, such as protein truncation test (PTT), multiplex ligation-dependent probe amplification (MLPA), southern blot, and real-time quantitative PCR (RT-PCR). But the major disadvantage of these methods is the inability to detect the non-truncating mutations, which account for 9.2% in the Han Chinese population. As a result, we still recommend that FAP testing should be performed using direct sequencing of the whole APC gene to detect the small-scale mutations along with MLPA to identify large insertion and deletions. If no mutation is detected, then testing for large gene rearrangements should be conducted.

To sum up, we reported that a novel heterozygous frame shift mutation c.1317delA (p.Ala440LeufsTer14) in the APC gene was responsible for FAP in a large Chinese pedigree. And we revealed a genotype-phenotype correlation between this novel mutation and extra colonic manifestations featuring by duodenal polyposis and sebaceous cysts. In the meantime, we conducted a literature review, piling up all the reported APC mutations causing FAP in the Han Chinese population. In summary, these data enhance understanding of the mutation spectrum of the APC gene causing FAP in Han Chinese and inform the development of effective guidelines in its genetic diagnosis and clinical management.
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![Pedigree of the FAP family. A four-generation family composed of 29 members from Sichuan, China, was recruited in the present study. The black arrow denotes the proband, solid symbols indicate affected individuals, and open symbols indicate unaffected individuals. In total, 12 family members were diagnosed with FAP. The disease exhibited a pattern of autosomal dominant inheritance. FAP, familial adenomatous polyposis; squares, males; circles, females; symbols with diagonal lines, deceased.](MMR-18-02-1423-g00){#f1-mmr-18-02-1423}

![Clinical characterization of the proband of this pedigree. (A) Two grape beaded polyps (red arrows) and some small polyps in the transverse colon. (B) A grape beaded polyp and some small polyps (red arrows) in the transverse colon.](MMR-18-02-1423-g01){#f2-mmr-18-02-1423}

![Novel mutation in the APC gene in this pedigree. (A) The novel heterozygous mutation c.1317delA (p.Ala440LysfsTer14) was validated using Sanger sequencing. (B) Multiple sequence alignment of APC proteins from various species. Red shades showed the premature termination of amino acids, which was resulted from the deletion. This region is highly conserved acrossdifferent species. APC, Adenomatous polyposis coli.](MMR-18-02-1423-g02){#f3-mmr-18-02-1423}

![Structure modeling of the functional domains of APC protein. (A) Structure of the APC protein, the red box denotes the site of the novel mutation, the green box shows the premature termination codon, the box with a dashed blue line indicates the truncated region of this protein, and the colored squares indicate the sub-domains in the APC protein. (B) Structure modeling of wild type and p.Ala440LeufsTer14 mutation of APC with SWISS-MODEL. Compared with wild type, the mutant leads to premature termination and potential loss of ability to bind with β-catenin. A440, Ala440; aa, amino acids; APC, Adenomatous polyposis coli.](MMR-18-02-1423-g03){#f4-mmr-18-02-1423}

###### 

Clinical information of the participants in the family.

  Family ID                                               Gender   Age (years)   Diagnosis   Age at diagnosis   Mutation      Polyp count   CRC (age of onset)   Extra-colonic features
  ------------------------------------------------------- -------- ------------- ----------- ------------------ ------------- ------------- -------------------- ------------------------
  I:1^[a](#tfn1-mmr-18-02-1423){ref-type="table-fn"}^     M        Deceased      Patient     Unspecified        Unspecified   Unspecified   Unspecified          Unspecified
  I:2^[a](#tfn1-mmr-18-02-1423){ref-type="table-fn"}^     F        Deceased      Normal      /                  /             /             /                    /
  II:1^[a](#tfn1-mmr-18-02-1423){ref-type="table-fn"}^    F        Deceased      Normal      /                  /             /             /                    /
  II:2^[a](#tfn1-mmr-18-02-1423){ref-type="table-fn"}^    M        Deceased      Patient     Unspecified        Unspecified   Unspecified   Unspecified          Unspecified
  II:3^[b](#tfn2-mmr-18-02-1423){ref-type="table-fn"}^    M        Deceased      Patient     Unspecified        Unspecified   Unspecified   Unspecified          Unspecified
  II:4                                                    F        75            Normal      /                  /             /             /                    /
  III:1                                                   M        64            Normal      /                  /             /             /                    /
  III:2                                                   F        62            Normal      /                  /             /             /                    /
  III:3^[b](#tfn2-mmr-18-02-1423){ref-type="table-fn"}^   M        Deceased      Patient     34                 c.1317delA    \>100         Unspecified          None
  III:4                                                   M        47            Patient     37                 c.1317delA    \>100         None                 None
  III:5                                                   F        46            Normal      /                  /             /             /                    /
  III:6                                                   M        45            Patient     38                 c.1317delA    \>100         None                 None
  III:7                                                   F        43            Patient     36                 c.1317delA    \>100         42                   None
  III:8                                                   M        45            Normal      /                  /             /             /                    /
  III:9                                                   M        53            Patient     44                 c.1317delA    \>100         None                 None
  III:10                                                  F        50            Normal      /                  /             /             /                    /
  III:11                                                  M        50            Patient     49                 c.1317delA    \>100         None                 None
  III:12                                                  F        48            Normal      /                  /             /             /                    /
  III:13                                                  F        48            Normal      /                  /             /             /                    /
  III:14                                                  F        47            Normal      /                  /             /             /                    /
  III:15                                                  M        43            Patient     40                 c.1317delA    \>100         43                   None
  IV:1                                                    M        39            Normal      /                  /             /             /                    /
  IV:2                                                    M        37            Normal      /                  /             /             /                    /
  IV:3                                                    M        24            Normal      /                  /             /             /                    /
  IV:4                                                    M        12            Normal      /                  /             /             /                    /
  IV:5                                                    F        24            Patient     21                 c.1317delA    \>100         None                 None
  IV:6                                                    M        19            Patient     16                 c.1317delA    \>100         None                 None
  IV:7                                                    F        20            Normal      /                  /             /             /                    /
  IV:8                                                    F        22            Normal      /                  /             /             /                    /

I1, I2, II1, II2, II3 were deceased prior to the present study, their information was collected from their medical records.

III3 was deceased following participation in the present study and donated his blood sample. M, male; F, female; /, not applicable; CRC, colorectal cancer.

###### 

Reported *APC* mutations causing familial adenomatous polyposis in the Han Chinese population.

  Author, year           Mutation in *APC* gene (Han Chinese)                                                        Codon   Mutation types   Occurrence   (Refs.)
  ---------------------- ------------------------------------------------------------------------------------------- ------- ---------------- ------------ -----------------------------------------------------------------------------------------------------------------
  Liu *et al*, 2005      c.366delG(p.Phe123LeufsX2)                                                                  123     Frameshift       1            ([@b20-mmr-18-02-1423])
  Liu *et al*, 2005      c.387insT(p.Glu129AspfsX10)                                                                 129     Frameshift       1            ([@b20-mmr-18-02-1423])
  Liu *et al*, 2005      c.541insA(p.Gln181ThrfsX12)                                                                 181     Frameshift       1            ([@b20-mmr-18-02-1423])
  Liu *et al*, 2005      c.637C\>T(p.Arg213X)                                                                        213     Nonsense         1            ([@b20-mmr-18-02-1423])
  Pang *et al*, 2001     c.646C\>T (p.Arg216X)                                                                       216     Nonsense         1            ([@b21-mmr-18-02-1423])
  Cai *et al*, 2008      c.694C\>T(p.Arg232X)                                                                        232     Nonsense         1            ([@b22-mmr-18-02-1423])
  Cai *et al*, 2008      c.763_764insA(p.His255GlnfsX2)                                                              255     Frameshift       1            ([@b22-mmr-18-02-1423])
  Zhang *et al*, 2016    c.794_795insG (p.Val266SerfsX11)                                                            266     Frameshift       1            ([@b23-mmr-18-02-1423])
  Liu *et al*, 2005;     c.847C\>T(p.Arg283X)                                                                        283     Nonsense         2            ([@b20-mmr-18-02-1423],[@b21-mmr-18-02-1423])
  Pang *et al*, 2001                                                                                                                                       
  Liu *et al*, 2005      c.1213C\>T(p.Arg405X)                                                                       405     Nonsense         1            ([@b20-mmr-18-02-1423])
  Pang *et al*, 2018     c.1317delA (p.Ala440LeufsX14)                                                               440     Frameshift       Novel        The present study
  Sheng *et al*, 2010    c.1327G\>T (p.Glu443X)                                                                      443     Nonsense         1            ([@b24-mmr-18-02-1423])
  Liu *et al*, 2005      c.1495C\>T(p.Arg499X)                                                                       499     Nonsense         1            ([@b20-mmr-18-02-1423])
  Jang *et al*, 2010     c.1548G\>C (p.Lys516Asn)                                                                    516     Missense         1            ([@b25-mmr-18-02-1423])
  Jang *et al*, 2010     c.1766T\>A (p.Leu589X)                                                                      589     Nonsense         1            ([@b25-mmr-18-02-1423])
  Song *et al*, 2013     c.1828_1829insG (p.Asp610GlyfsX23)                                                          610     Frameshift       1            ([@b26-mmr-18-02-1423])
  Chen *et al*, 2011     c.1999 C\>T (p. Gln667X)                                                                    667     Nonsense         1            ([@b27-mmr-18-02-1423])
  Jang *et al*, 2010     c.2016_2047del (p.Ser673LeufsX10)                                                           673     Frameshift       1            ([@b25-mmr-18-02-1423])
  Cai *et al*, 2008      c.2031_2034delCAGT (p.Ser678MetfsX39)                                                       678     Frameshift       1            ([@b22-mmr-18-02-1423])
  Zhang *et al*, 2016    c.2142_2143insG (p.His715AlafsX19)                                                          715     Frameshift       1            ([@b23-mmr-18-02-1423])
  Cai *et al*, 2008      c.2240C\>G(p.Ser747X)                                                                       747     Nonsense         1            ([@b22-mmr-18-02-1423])
  Sheng *et al*, 2010    c.2336_2337insT (p.Leu779PhefX9)                                                            779     Frameshift       1            ([@b24-mmr-18-02-1423])
  Jang *et al*, 2010     c.2510C\>G (p.Ser837X)                                                                      837     Nonsense         1            ([@b25-mmr-18-02-1423])
  Liu *et al*, 2005      c.2547_2550delTAGA (p.Asp849GlufsX11)                                                       849     Frameshift       1            ([@b20-mmr-18-02-1423])
  Li *et al*, 2017       c.2971G\>T (p.Glu991X)                                                                      991     Nonsense         1            ([@b28-mmr-18-02-1423])
  Pang *et al*, 2001     c.3067_3068insA (p.Thr1023AsnfsX6)                                                          1,023   Frameshift       1            ([@b21-mmr-18-02-1423])
  Cai *et al*, 2008      c.3182_3183delAA (p.Lys1061ThrfsX3)^[a](#tfn3-mmr-18-02-1423){ref-type="table-fn"}^         1,061   Frameshift       1            ([@b22-mmr-18-02-1423])
  Liu *et al*, 2005;     c.3183_3187delACAAA                                                                         1,061   Frameshift       5            ([@b20-mmr-18-02-1423]--[@b24-mmr-18-02-1423])
  Pang *et al*, 2001;    (p.Lys1061LysfsX2)^[a](#tfn3-mmr-18-02-1423){ref-type="table-fn"}^                                                                
  Cai *et al*, 2008;                                                                                                                                       
  Sheng *et al*, 2010                                                                                                                                      
  Wang *et al*, 2008;    c3184_3187delCAAA                                                                           1,061   Frameshift       3            ([@b29-mmr-18-02-1423]--[@b31-mmr-18-02-1423])
  Chen *et al*, 2015;    (p.Gln1061AspfsX59)                                                                                                               
  Chen *et al*, 2015                                                                                                                                       
  Jang *et al*, 2010     c.3180_3184del (p.Gln1062X)                                                                 1,062   Nonsense         1            25
  Cai *et al*, 2008;     c.3202_3205delTCAA                                                                          1,068   Frameshift       3            ([@b22-mmr-18-02-1423],[@b24-mmr-18-02-1423])
  Sheng *et al*, 2010    (p.Ser1068GlyfsX57)                                                                                                               
  Zhang *et al*, 2017    c.3418delC (p.Pro1140Leufx25)                                                               1,140   Frameshift       1            ([@b32-mmr-18-02-1423])
  Cai *et al*, 2008      c.3576delA(p.Lys1192AsnfsX73)                                                               1,192   Frameshift       1            ([@b22-mmr-18-02-1423])
  Zhu *et al*, 2012      c.3587C\>A(p.Ser1196X)                                                                      1,196   Frameshift       1            ([@b33-mmr-18-02-1423])
  Liu *et al*, 2005      c.3667delC (p.Ser1223LeufsX42)                                                              1,223   Frameshift       1            ([@b20-mmr-18-02-1423])
  Chen *et al*, 2015     c.3921_3924delAAAA (p.Ile1307MetfsX13)^[a](#tfn3-mmr-18-02-1423){ref-type="table-fn"}^      1,307   Frameshift       1            ([@b31-mmr-18-02-1423])
  Sheng *et al*, 2010    c.3923_3929delAAGAAAA (p.Lys1308ArgfsX11)^[a](#tfn3-mmr-18-02-1423){ref-type="table-fn"}^   1,308   Frameshift       1            ([@b24-mmr-18-02-1423])
  Chen *et al*, 2015     c.3926_3929delAAAA^[a](#tfn3-mmr-18-02-1423){ref-type="table-fn"}^                          1,309   Frameshift       1            ([@b30-mmr-18-02-1423])
  Liao *et al*, 2014     c.3922_3925 del AAAG (p. Glu1309Argfs ×11)                                                  1,309   Frameshift       1            ([@b34-mmr-18-02-1423])
  Wang *et al*, 2008;    c.3926_3930delAAAAG                                                                         1,309   Frameshift       6            ([@b29-mmr-18-02-1423]--[@b31-mmr-18-02-1423],[@b34-mmr-18-02-1423])
  Chen *et al*, 2015;    (p.Glu1309AspfsX4)                                                                                                                
  Chen *et al*, 2015;                                                                                                                                      
  Liao *et al*, 2014                                                                                                                                       
  Liu *et al*, 2005;     c.3927_3931delAAAGA                                                                         1,309   Frameshift       10           ([@b20-mmr-18-02-1423],[@b22-mmr-18-02-1423],[@b24-mmr-18-02-1423],[@b35-mmr-18-02-1423]-[@b37-mmr-18-02-1423])
  Cai *et al*, 2008;     (p.Glu1309AspfsX4)                                                                                                                
  Sheng *et al*, 2010;                                                                                                                                     
  Zhang *et al*, 2016;                                                                                                                                     
  Pan *et al*, 2014;                                                                                                                                       
  Gan *et al*, 1994                                                                                                                                        
  Chen *et al*, 2015     c4127_4126delAT (p.Tyr1376LysfsX9)                                                          1,376   Frameshift       1            ([@b31-mmr-18-02-1423])
  Sheng *et al*, 2010    c.4179_4180GAdelinsT (p.Asp1394LeufsX21)                                                    1,394   Frameshift       1            ([@b24-mmr-18-02-1423])
  Cai *et al*, 2008      c.4209delC (p.Ser1404ProfsX11)                                                              1,404   Frameshift       1            ([@b22-mmr-18-02-1423])
  Liu *et al*, 2005      c.4391_4394delAGAG (p.Glu1464ValfsX8)                                                       1,464   Frameshift       1            ([@b20-mmr-18-02-1423])
  Wang *et al*, 2008;    c.5432C\>T (p. Ser1811Leu)^[a](#tfn3-mmr-18-02-1423){ref-type="table-fn"}^                  1,811   Missense         3            ([@b29-mmr-18-02-1423]--[@b31-mmr-18-02-1423])
  Chen *et al*, 2015;                                                                                                                                      
  Chen *et al*, 2015                                                                                                                                       
  Liu *et al*, 2005      c.5947_5950delGAAA (p.Glu1983MetfsX60)                                                      1,983   Frameshift       1            ([@b20-mmr-18-02-1423])
  Jiang *et al*, 2015    c.1936-2148 del                                                                             /       Large deletion   1            ([@b3-mmr-18-02-1423])
  Sheng *et al*, 2010    10A (Alternative exon) and Exon11                                                           /       Large deletion   1            ([@b24-mmr-18-02-1423])
  Sheng *et al*, 2010    Exon15 start                                                                                /       Large deletion   1            ([@b24-mmr-18-02-1423])
  Zhang *et al*, 2016    c.423_8532del                                                                               /       Large deletion   1            ([@b38-mmr-18-02-1423])
  Sheng *et al*, 2010    c.532-2A\>T                                                                                 /       Intronic         1            ([@b24-mmr-18-02-1423])
  Sheng *et al*, 2010    c.657+1G\>A                                                                                 /       Intronic         1            ([@b24-mmr-18-02-1423])
  Zhang *et al*, 2016    c.1312+1G\>A                                                                                /       Intronic         1            ([@b23-mmr-18-02-1423])

Hotspot mutation sites of the APC gene in Han Chinese population. *APC, Adenomatous polyposis coli*.
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